{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:08:47Z","timestamp":1761718127816},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.reuma.2009.06.004","type":"journal-article","created":{"date-parts":[[2010,1,22]],"date-time":"2010-01-22T10:29:40Z","timestamp":1264156180000},"page":"121-127","source":"Crossref","is-referenced-by-count":3,"title":["Revisi\u00f3n sistem\u00e1tica del uso de adalimumab en enfermedades autoinmunes. Eficacia y seguridad en 54 pacientes"],"prefix":"10.1016","volume":"6","author":[{"given":"C\u00e1ndido","family":"D\u00edaz-Lagares","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Belenguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2009.06.004_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O\u2019Shea","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.reuma.2009.06.004_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2009.06.004_bib3","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2009.06.004_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra032906","article-title":"New drugs for rheumatoid arthritis","volume":"350","author":"Olsen","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reuma.2009.06.004_bib5","doi-asserted-by":"crossref","unstructured":"Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. An Rheum Dis. 2007;66(suppl III):iii2\u201322","DOI":"10.1136\/ard.2007.081430"},{"key":"10.1016\/j.reuma.2009.06.004_bib6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"issue":"Suppl II","key":"10.1016\/j.reuma.2009.06.004_bib7","doi-asserted-by":"crossref","first-page":"ii70","DOI":"10.1136\/ard.61.suppl_2.ii70","article-title":"Adalimumab (a fully human anti-tumor necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials","volume":"61","author":"Rau","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"D\u00edaz-Llopis","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.reuma.2009.06.004_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/s-2008-1027361","article-title":"Anti-TNF alpha therapy in patients with chronic non infectious uveitis: The expereince of Jules Gonin Eye Hospital","volume":"225","author":"Petropoulos","year":"2008","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"10.1016\/j.reuma.2009.06.004_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight threatening uveitis in Beh\u00e7et disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.reuma.2009.06.004_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et\u2032s disease?","volume":"66","author":"Van laar","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib12","first-page":"131","article-title":"Tratamiento con Adalimumab-nuevo anti-TNF- del s\u00edndrome de Vogt-Koyanagi-Harada. Adalimumab therapy for Vogt-Koyanagi-Harada","volume":"82","author":"D\u00edaz llopis","year":"2007","journal-title":"Arch Soc Esp Ophtalmol"},{"key":"10.1016\/j.reuma.2009.06.004_bib13","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s10067-006-0375-2","article-title":"Treatment of refractory temporal arteritis with adalimumab","volume":"26","author":"Ahmed","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib14","first-page":"304","article-title":"Refractory Takayasu's arteritis successfully treated with the human, monoclonal anti-tumor necrosis factor antibody adalimumab","volume":"24","author":"Tato","year":"2005","journal-title":"Int Angiol"},{"key":"10.1016\/j.reuma.2009.06.004_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0151-9638(06)70938-3","article-title":"Vasculite avec ulc\u00e9rations cutan\u00e9es au cours de la polyarthrite rhumato\u00efde: traitement par anti TNF","volume":"133","author":"Thirion","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.reuma.2009.06.004_bib16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/rheumatology\/kem229","article-title":"Prolonged response to anti-tumor necrosis factor treatment with Adalimumab (Humira) in relapsing polychondritis complicated by aortitis","volume":"46","author":"Seymour","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2009.06.004_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archderm.142.1.17","article-title":"Adalimumab for treatment of cutaneus sarcoidosis","volume":"146","author":"Heffernan","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10067-005-0037-9","article-title":"Treatment of therapy-resistant sarcoidosis with adalimumab","volume":"25","author":"Callejas-Rubio","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib19","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaad.2005.02.023","article-title":"Ulcerative cutaneus sarcoidosis responding to adalimumab","volume":"53","author":"Philips","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib20","first-page":"507","article-title":"Urticaria and angioedema in a patient with Beh\u00e7et\u2032s disease treated with adalimumab","volume":"25","author":"S\u00e1nchez-Cano","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib21","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2005.044453","article-title":"Fatal excerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab","volume":"65","author":"Allanore","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1055\/s-2004-826865","article-title":"Longterm outcome of TNF blockade in adult-onset Still\u2032s disease","volume":"129","author":"Dechant","year":"2004","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.reuma.2009.06.004_bib23","first-page":"733","article-title":"Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still\u2032s disease: the first case report","volume":"23","author":"Benucci","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Callejas-Rubio","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.reuma.2009.06.004_bib25","doi-asserted-by":"crossref","unstructured":"Huynh N, Cervantes-Casta\u00f1eda RA, Bhat P, Gallagher MJ. Biologic response modifier therapy for psoriatic ocular inflammatory disease. Ocul Immunol Inflamm. 2008; 16: 89\u20133.","DOI":"10.1080\/09273940802023786"},{"key":"10.1016\/j.reuma.2009.06.004_bib26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MD.0b013e318190f170","article-title":"A Systematic review of the off-label use of biological therapies in systemic autoimmune diseases","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.reuma.2009.06.004_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","article-title":"Biologics in the treatment of uveitis","volume":"18","author":"Imrie","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.reuma.2009.06.004_bib28","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differencial effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.reuma.2009.06.004_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiophatic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2009.06.004_bib30","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumor necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2009.06.004_bib31","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiophatic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib32","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.reuma.2009.06.004_bib34","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis","volume":"149","author":"Vazquez-Cobian","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.reuma.2009.06.004_bib35","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular enema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.reuma.2009.06.004_bib36","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","article-title":"Treatment of longstanding active giant cell arteritis with infliximab: report of four cases","volume":"44","author":"Cantini","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.06.004_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/rheumatology\/41.3.347","article-title":"Anti-tumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs","volume":"41","author":"Airo","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2009.06.004_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.62.4.373","article-title":"Successful treatment of resistant giant cell arteritis with etanercept","volume":"62","author":"Tan","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/ard.62.11.1116","article-title":"Experience with infliximab (anti-TNF alpha monoclonal antibody) as monotherapy for giant cell arteritis","volume":"62","author":"Andonopoulos","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib40","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/art.20300","article-title":"Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis","volume":"50","author":"Hoffmann","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.06.004_bib41","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/rheumatology\/keh661","article-title":"Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?","author":"Della Rosa","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.reuma.2009.06.004_bib42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10067-006-0227-0","article-title":"Infliximab in Takayasu arteritis: a safe alternative?","volume":"26","author":"Karageorgaki","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib43","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/01.rhu.0000173218.28013.3e","article-title":"Infliximab-responsive uveitis an vasculitis in a patient with Takayasu arteritis","volume":"11","author":"Jolly","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2169\/internalmedicine.45.1377","article-title":"Infliximab is effective for Takayasu arteritis refractory to glucocorticoids and methotrexate","volume":"45","author":"Tanaka","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.reuma.2009.06.004_bib45","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reuma.2009.06.004_bib46","doi-asserted-by":"crossref","unstructured":"Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 146: 631\u20139.","DOI":"10.7326\/0003-4819-146-9-200705010-00005"},{"key":"10.1016\/j.reuma.2009.06.004_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","article-title":"Efficacy and safety of switching from infliximab to adalimumab. A comparative controlled study","volume":"65","author":"Nikas","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2009.06.004_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009740510026887","article-title":"Adalimumab restores clinical response in patients with secondary loss of efficacy from infliximab or etanercept: results of the STURE registry at Karolinska University Hospital","volume":"34","author":"Wick","year":"2005","journal-title":"Scand Rheumatol"},{"key":"10.1016\/j.reuma.2009.06.004_bib49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated witn tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2009.06.004_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X09002824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X09002824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T08:55:04Z","timestamp":1558774504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X09002824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1699258X09002824"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2009.06.004","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}